The RevoLix<sup>™</sup> 2 μm Continuous Wave Laser Vaporesection for the Treatment of Benign Prostatic Hyperplasia: Five-Year Follow-Up

Si, Jiemin; Gu, Baojun; Chen, Zhong; Fu, Qiang

doi:10.1089/pho.2015.4070

Cited by 3 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These RR are similar to HoLEP [2, 3, 27], TURP [2, 3, 27], PVP [2, 3, 27], and ThuVEP [8, 17, 24] series. RR ranging from 1.3 to 2.1% for bladder neck contractures [12, 13, 24], from 2.1 to 3.5% for urethral strictures [11-13, 25, 26] and from 1.2 to 2.6% for regrowth of prostatic tissue [12, 14] have been reported for ThuVaRP at 24-month follow-up. Due to lesser tissue removal with the ThuVaRP procedure in our study, one would expect a higher RR for regrowth of prostatic tissue with a longer follow-up.…”

Section: Discussionmentioning

confidence: 99%

Thulium Vaporesection of the Prostate and Thulium Vapoenucleation of the Prostate: A Retrospective Bicentric Matched-Paired Comparison with 24-Month Follow-Up

et al. 2017

View full text Add to dashboard Cite

Introduction: To evaluate the intermediate-term outcomes of thulium vapoenucleation of the prostate (ThuVEP) and thulium vaporesection of the prostate (ThuVaRP) in patients with benign prostate obstruction (BPO). Materials and Methods: A bicentric retrospective matched-paired comparison of patients treated by ThuVEP (n = 80) or ThuVaRP (n = 80) was performed. The patients were preoperatively assessed with International Prostate Symptom Score (IPSS), quality of life (QoL), post-void residual urine (PVR), maximum urinary flow rate (Qmax), prostatespecific antigen (PSA) and re-evaluated at 12- and 24-month follow-up. Results: Median prostate volume was 65 mL and not different between the groups. The immediate re-operation rate was significantly different between ThuVEP and ThuVaRP (5 vs. 0%, p ≤ 0.0434). IPSS, QoL, Qmax and PVR had improved significantly compared to preoperative assessment in both groups at 12- and 24-month follow-up (p ≤ 0.001). Median Qmax (18.2 vs. 21.0 mL/s) and PVR (29.4 vs. 0 mL) were significantly different between ThuVEP and ThuVaRP at 24-month follow-up (p ≤ 0.001), while IPSS and QoL showed no differences between the groups. However, the PSA reduction was significantly higher after ThuVEP compared to ThuVaRP (78.93 vs. 23.39%, p ≤ 0.006) at 24-month follow-up. Conclusions: ThuVEP and ThuVaRP are safe and efficacious procedures for patients with BPO. Although the peri-operative re-intervention rates were lower after ThuVaRP, the low PSA reduction rate after ThuVaRP at 24-month follow-up favours the ThuVEP procedure.

show abstract

Section: Discussionmentioning

confidence: 99%

Thulium Vaporesection of the Prostate and Thulium Vapoenucleation of the Prostate: A Retrospective Bicentric Matched-Paired Comparison with 24-Month Follow-Up

et al. 2017

View full text Add to dashboard Cite

show abstract

Ablative Verfahren: Resektion

Netsch¹

2022

Benignes Prostatasyndrom

View full text Add to dashboard Cite

Ablative Procedures: Resection

Netsch

2023

Benign Prostate Syndrome

View full text Add to dashboard Cite

The RevoLix^™ 2 μm Continuous Wave Laser Vaporesection for the Treatment of Benign Prostatic Hyperplasia: Five-Year Follow-Up

Abstract: The 2 μm CW laser is a safe and effective option for the treatment of BPH. At the 5-year follow-up, the long-term clinical efficacy and safety are excellent, with low incidence of complications.

Cited by 3 publications

References 18 publications

Thulium Vaporesection of the Prostate and Thulium Vapoenucleation of the Prostate: A Retrospective Bicentric Matched-Paired Comparison with 24-Month Follow-Up

Thulium Vaporesection of the Prostate and Thulium Vapoenucleation of the Prostate: A Retrospective Bicentric Matched-Paired Comparison with 24-Month Follow-Up

Ablative Verfahren: Resektion

Ablative Procedures: Resection

Contact Info

Product

Resources

About

The RevoLix™ 2 μm Continuous Wave Laser Vaporesection for the Treatment of Benign Prostatic Hyperplasia: Five-Year Follow-Up

Abstract: The 2 μm CW laser is a safe and effective option for the treatment of BPH. At the 5-year follow-up, the long-term clinical efficacy and safety are excellent, with low incidence of complications.

Cited by 3 publications

References 18 publications

Thulium Vaporesection of the Prostate and Thulium Vapoenucleation of the Prostate: A Retrospective Bicentric Matched-Paired Comparison with 24-Month Follow-Up

Thulium Vaporesection of the Prostate and Thulium Vapoenucleation of the Prostate: A Retrospective Bicentric Matched-Paired Comparison with 24-Month Follow-Up

Ablative Verfahren: Resektion

Ablative Procedures: Resection

Contact Info

Product

Resources

About

The RevoLix^™ 2 μm Continuous Wave Laser Vaporesection for the Treatment of Benign Prostatic Hyperplasia: Five-Year Follow-Up